Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03328091 · ClinicalTrials.gov registry record · NA

Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)

A NA study, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
662
Enrollment target

NCT03328091: Completed NA study, sponsored by Dana-Farber Cancer Institute.

NCT03328091 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 662 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03328091, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
662 participants
Enrollment target

Study Summary

This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer.

Primary Outcome

The proportion of participants who test positive for pathogenic or likely pathogenic variants

Interventions

  • OTHER Traditional pre-test genetic counseling
  • OTHER Pre-test video education

Trial Details

FieldValue
Enrollment Target 662 participants
Start Date 2017-11-21
Est. Completion 2020-02-13
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT03328091 record still lists

NCT03328091 is an interventional study that assigns participants to a tested intervention. The registered 662 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (53% lower).

The record links to 0 conditions, and to 2 interventions - of which Traditional pre-test genetic counseling is the first listed.

NCT03328091 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03328091 about?

NCT03328091 is a clinical study titled "Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)". This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer.

What is the current status of trial NCT03328091?

This trial is currently completed. It is a NA study. The enrollment target is 662 participants. The study started on 2017-11-21. Estimated completion is 2020-02-13.

What interventions are being tested in trial NCT03328091?

The interventions under investigation include: Traditional pre-test genetic counseling (OTHER), Pre-test video education (OTHER).

Who is sponsoring clinical trial NCT03328091?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03328091's enrollment target sits among peer trials

662 155th of 2000 higher than 1,846 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05254743 · 662 participants · Phase 3

    A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • NCT07164443 · 663 participants · Phase 3

    A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • NCT06607341 · 664 participants · NA

    Community Engagement Alliance Against Disparities

  • NCT01185132 · 660 participants · Phase 3

    Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03328091, the US trial registry maintained by the National Library of Medicine. NCT03328091 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.